Core Insights - Sunrise Realty Trust, Inc. has committed $48 million of a $69 million B-note for refinancing a 15-property portfolio of Graduate by Hilton hotels, totaling $406 million in proceeds [1][2][3] Group 1: Company Overview - Sunrise Realty Trust, Inc. (SUNS) is an institutional commercial real estate lender focused on transitional CRE projects primarily in the Southern United States [4] - The company aims to provide flexible financing solutions that create near-term value, collateralized by top-tier assets in rapidly expanding markets [4][5] Group 2: Investment Strategy - The investment strategy involves targeting university-anchored lodging due to high demand and potential for portfolio synergies [2] - The portfolio includes upscale hotels located in major university markets such as the University of Michigan, University of Virginia, and UC Berkeley [2] Group 3: Partnership and Market Position - The transaction highlights the company's ability to identify opportunities in markets with captive demand and limited new supply [3] - The CEO emphasizes the importance of cultivating long-term partnerships to support the vision for premier assets [3]

HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event:Oppenheime ...

Following the Addition of General Jack Keane, REalloys Further Strengthens Board with Addition of Former Vice Chairman of UBS Investment Bank Blackboxstocks/REalloys Form S-4 has been declared effective by the SEC, and, pending NASDAQ listing approval, the company expects to close the merger DALLAS, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Blackboxstocks Inc. (NASDAQ: BLBX) (“Blackboxstocks” or the “Company”) today announced that its merger target, REalloys Inc. (“REalloys”), has entered into a designate director ...

CLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in The Citizens Life Sciences Conference on Wednesday, March 11, 2026, in Miami, FL. Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate i ...

Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion technology Strengthens positioning in China’s growing cell therapy market and supports cross-border partnerships HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri”, the “Company”, “we”, “our” or “us”) (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its ...

Adds three new denture base shades (DP, LP, RP) to better match diverse natural gum tones and address real patient diversityExpands production flexibility for dental laboratoriesReinforces market leadership in monolithic, multi-material denture printingDelivers up to 300% faster production, over 50% less manual labor, and one-day turnaround (vs. five days traditional) — slashing labor, streamlining workflows, and cutting costs for labs ROCK HILL, S.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Today, 3D Systems (NY ...

Leadership Transition - GPGI, Inc. announced the departure of Husky Technologies' CEO Bradley Selleck and CFO John Linker, effective April and March 2026 respectively, for personal reasons [1][2] - Active searches for their replacements are underway, with no expected disruptions to the company's strategic priorities or operations during this transition [2] Company Outlook - Mr. Selleck emphasized Husky's strong position in a favorable industry and the growth opportunities presented by GPGI's ownership, highlighting the potential for profitable growth [3] - Mr. Linker noted GPGI's financial strength and commitment to innovation as key factors for Husky's continued success [3] - GPGI's Executive Chairman David Cote expressed confidence in the ongoing leadership search and the implementation of the Resolute Operating System to support Husky's growth [3] Company Profile - GPGI, Inc. is a diversified platform managed by Resolute Holdings, focused on acquiring and scaling high-quality businesses [4] - Husky, founded in 1953, is a leader in highly engineered equipment and aftermarket services, providing solutions for manufacturing a variety of plastic products [5]

Core Viewpoint - Vaxart, Inc. is set to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, highlighting its focus on developing oral vaccines using a proprietary delivery platform [1][2]. Company Overview - Vaxart is a clinical-stage biotechnology company specializing in oral recombinant vaccines that can be stored and shipped without refrigeration, thus eliminating needle-stick injury risks [3]. - The company is developing vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV), marking its entry into immune-oncology [3]. - Vaxart has filed extensive domestic and international patent applications for its oral vaccination technology, which utilizes adenovirus and TLR3 agonists [3]. Presentation Details - The presentation is scheduled for February 25, 2026, at 4:00 PM ET, and will be available for 30 days on the company's investor relations website [2]. - Vaxart will also engage in one-on-one meetings during the conference for interested investors [2].

WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), held February 18-21, 2026 in Stockholm, Sweden. “We are excited to share follow-up data out to 20 weeks fro ...

Patent Covers Generation of Multiple Audience-Adaptive Commentary Video Variants While Preserving Factual IntegrityFREEHOLD, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that its subsidiary, Avalon Quantum AI LLC, has filed a new U.S. provisional patent application covering an artificial intelligenc ...